TERF1 and central nervous system cancer: In particular, TRF1 chemical inhibitors have been demonstrated to recapitulate the TRF1 knockdown phenotype and reduce tumor growth in xenografts from patient‐derived primary Glioma Stem Cells (GSCs) (Bejarano et al, 2019).